myeloma

Oncopeptides AB (OTC: ONPPF) has some good news and some bad news from the updated results from Phase 3 OCEAN study of Pepaxto (melflufen) plus dexamethasone in patients with relapsed / refractory multiple myeloma who have received 2 – 4 prior lines of therapy. The good news...

Bluebird bio Inc (NASDAQ: BLUE)'s multiple myeloma therapy coud have a "disruptive impact" on treatment of the disease, according to Goldman Sachs. The Analyst Goldman Sachs' Salveen Richter maintains a Buy rating on bluebird's stock and raised the price target from $186 to...

Wedbush analyst David Nierengarten maintains his Outperform rating and $95 target price on bluebird bio Inc (NASDAQ: BLUE), which announced positive results from its early-stage cancer study. Cambridge, Massachusetts-based bluebird bio said early data from its ongoing Phase 1 study of bb2121 showed...

Bluebird bio Inc (NASDAQ: BLUE) announced positive early data from its ongoing open-label Phase 1 CRB-401 study with its CAR T candidate, bb2121, in patients with relapsed and/or refractory multiple myeloma. Although the initial early data is encouraging, there are potential risk of CRS [...

Amgen, Inc. (NASDAQ: AMGN) announced that the Phase 3 CLARION trial for Kyprolis in first-line multiple myeloma (MM) did not meet the primary endpoint. Goldman Sachs’ Terence Flynn maintains a Buy rating on the company, while lowering the price target from $206 to $198. Disappointing Data...